S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
Positive News Sentiment  
NASDAQ:BDSX

Biodesix - BDSX Stock Forecast, Price & News

$1.72
-0.01 (-0.58%)
(As of 03/28/2023 05:12 PM ET)
Add
Compare
Today's Range
$1.67
▼
$1.77
50-Day Range
$1.52
▼
$2.50
52-Week Range
$0.96
▼
$3.00
Volume
42,073 shs
Average Volume
119,715 shs
Market Capitalization
$134.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50

Biodesix MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
397.1% Upside
$8.50 Price Target
Short Interest
Healthy
0.95% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$149,600 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.81) to ($0.68) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.37 out of 5 stars

Medical Sector

231st out of 1,002 stocks

Medical Laboratories Industry

8th out of 26 stocks

See Top Rated MarketRank™ Stocks Here

BDSX stock logo

About Biodesix (NASDAQ:BDSX) Stock

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.

Receive BDSX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biodesix and its competitors with MarketBeat's FREE daily newsletter.

BDSX Stock News Headlines

March 15, 2023 | finance.yahoo.com
Bullish Biodesix, Inc. (NASDAQ:BDSX) insiders filled their treasuries with US$34m worth of stock over last year
March 8, 2023 | finance.yahoo.com
Biodesix, Inc. (NASDAQ:BDSX) Q4 2022 Earnings Call Transcript
March 28, 2023 | Weiss Ratings (Ad)
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
March 6, 2023 | finance.yahoo.com
Biodesix Announces Fourth Quarter and Fiscal Year End 2022 Results and Highlights
March 6, 2023 | finance.yahoo.com
Biodesix, Inc. (BDSX) Reports Q4 Loss, Misses Revenue Estimates
February 21, 2023 | finance.yahoo.com
Biodesix to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
February 16, 2023 | finance.yahoo.com
Even after rising 15% this past week, Biodesix (NASDAQ:BDSX) shareholders are still down 39% over the past year
December 19, 2022 | finance.yahoo.com
Biodesix Announces First Four Private Payer Coverage Policies for the Nodify XL2® Test
March 28, 2023 | Weiss Ratings (Ad)
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
December 16, 2022 | finance.yahoo.com
Biodesix Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors
December 12, 2022 | finance.yahoo.com
Biodesix Ranked Top Proteomics Solutions Company by Life Sciences Review Magazine
November 21, 2022 | finance.yahoo.com
Biodesix Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
November 17, 2022 | finance.yahoo.com
Biodesix Announces Pricing of $35.1 Million Upsized Public Offering of Common Stock
November 16, 2022 | finance.yahoo.com
Biodesix Announces Senior Secured Financing Agreement with Perceptive Advisors for Up to $50 Million
November 16, 2022 | finance.yahoo.com
Biodesix Announces Proposed Public Offering of Common Stock
November 10, 2022 | finance.yahoo.com
Biodesix Presents New Data from the INSIGHT Study at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
November 9, 2022 | finance.yahoo.com
Biodesix Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags
November 3, 2022 | finance.yahoo.com
Biodesix Announces Third Quarter 2022 Results and Highlights
October 20, 2022 | finance.yahoo.com
Biodesix to Report Third Quarter 2022 Financial Results on November 3, 2022
October 17, 2022 | finance.yahoo.com
Boulder's Biodesix snags $20M contract, plans move to larger space in Louisville
October 17, 2022 | businesswire.com
Biodesix Awarded U.S. Federal Supply Schedule Contract for Its Comprehensive Lung Cancer Diagnostic Testing Solutions - Business Wire
October 17, 2022 | finance.yahoo.com
Biodesix Awarded U.S. Federal Supply Schedule Contract for Its Comprehensive Lung Cancer Diagnostic Testing Solutions
October 14, 2022 | businesswire.com
Insights on the Liquid Biopsy Global Market to 2028 - Featuring Biocept, Epigenomics, Exosome Diagnostics and Lariat Biosciences Among Others - ResearchAndMarkets.com - Business Wire
October 13, 2022 | seekingalpha.com
Biodesix expects Q3 revenue above the consensus - Seeking Alpha
October 12, 2022 | streetinsider.com
Biodesix Announces Preliminary Revenue for Third Quarter 2022 - StreetInsider.com
October 12, 2022 | businesswire.com
Biodesix to Present Data at the CHEST 2022 Annual Meeting Demonstrating High Sensitivity of the Nodify XL2® Blood-Based Lung Nodule Test in Various Patient Populations, Including Individuals Participating in Lung Cancer Screening Programs - Business Wire
October 12, 2022 | finance.yahoo.com
Biodesix to Present Data at the CHEST 2022 Annual Meeting Demonstrating High Sensitivity of the Nodify XL2® Blood-Based Lung Nodule Test in Various Patient Populations, Including Individuals Participating in Lung Cancer Screening Programs
See More Headlines
Receive BDSX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biodesix and its competitors with MarketBeat's FREE daily newsletter.

BDSX Company Calendar

Last Earnings
3/06/2023
Today
3/28/2023
Next Earnings (Estimated)
5/10/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BDSX
CUSIP
N/A
CIK
1439725
Web
www.biodesix.com
Phone
303-417-0500
Fax
N/A
Employees
218
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.50
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+394.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.59)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-65,450,000.00
Net Margins
-171.27%
Pretax Margin
-171.27%
Return on Equity
-741.60%
Return on Assets
-83.92%

Debt

Debt-to-Equity Ratio
1.21
Current Ratio
2.34
Quick Ratio
2.34

Sales & Book Value

Annual Sales
$38.21 million
Price / Sales
3.51
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.27 per share
Price / Book
6.37

Miscellaneous

Outstanding Shares
77,970,000
Free Float
39,143,000
Market Cap
$134.11 million
Optionable
Not Optionable
Beta
1.50

Key Executives

  • Mr. Scott HuttonMr. Scott Hutton (Age 50)
    Pres, CEO & Director
    Comp: $586.3k
  • Ms. Robin Harper CowieMs. Robin Harper Cowie (Age 42)
    CFO, Sec. & Treasurer
    Comp: $349.05k
  • Mr. Ryan H. Siurek (Age 50)
    Chief Accounting Officer
    Comp: $294.87k
  • Dr. Heinrich Röder
    Founder & CTO
  • Dr. Robert W. Georgantas III (Age 51)
    Ph.D., Chief Scientific Officer
  • Mr. Jeffrey A. Bojar
    VP of Legal and Regulatory Affairs
  • Mr. Matt Stauffer
    VP of Sales
  • Dr. Paul J. Beresford
    Chief Bus. Officer
  • Dr. Gary Anthony Pestano Ph.D. (Age 55)
    Chief Devel. Officer
  • Ms. Bobbi Coffin
    Chief Growth Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













BDSX Stock - Frequently Asked Questions

Should I buy or sell Biodesix stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biodesix in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BDSX shares.
View BDSX analyst ratings or view top-rated stocks.

What is Biodesix's stock price forecast for 2023?

4 equities research analysts have issued 1 year target prices for Biodesix's stock. Their BDSX share price forecasts range from $7.00 to $10.00. On average, they expect the company's stock price to reach $8.50 in the next year. This suggests a possible upside of 394.2% from the stock's current price.
View analysts price targets for BDSX or view top-rated stocks among Wall Street analysts.

How have BDSX shares performed in 2023?

Biodesix's stock was trading at $2.30 on January 1st, 2023. Since then, BDSX stock has decreased by 25.2% and is now trading at $1.72.
View the best growth stocks for 2023 here.

When is Biodesix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023.
View our BDSX earnings forecast.

How were Biodesix's earnings last quarter?

Biodesix, Inc. (NASDAQ:BDSX) issued its earnings results on Monday, March, 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by $0.02. The business earned $9.61 million during the quarter, compared to analyst estimates of $10.70 million. Biodesix had a negative net margin of 171.27% and a negative trailing twelve-month return on equity of 741.60%. During the same quarter in the previous year, the company earned ($0.49) EPS.

What guidance has Biodesix issued on next quarter's earnings?

Biodesix issued an update on its FY 2023 earnings guidance on Monday, March, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $52.00 million-$55.00 million, compared to the consensus revenue estimate of $52.51 million.

When did Biodesix IPO?

(BDSX) raised $76 million in an IPO on Wednesday, October 28th 2020. The company issued 4,200,000 shares at $17.00-$19.00 per share. Morgan Stanley and William Blair acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

What is Biodesix's stock symbol?

Biodesix trades on the NASDAQ under the ticker symbol "BDSX."

Who are Biodesix's major shareholders?

Biodesix's stock is owned by a variety of retail and institutional investors. Top institutional investors include AIGH Capital Management LLC (14.48%), Birchview Capital LP (11.97%), HighTower Advisors LLC (0.32%), Endurant Capital Management LP (0.30%), Millennium Management LLC (0.26%) and Legato Capital Management LLC (0.08%). Insiders that own company stock include Charles M Watts, Gary Anthony Pestano, Hany Massarany, Jack W Schuler, John Patience, Kieran O'kane, Matthew Strobeck, Robert William Georgantas III, Robin Harper Cowie, Ryan H Siurek and Scott Hutton.
View institutional ownership trends.

How do I buy shares of Biodesix?

Shares of BDSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biodesix's stock price today?

One share of BDSX stock can currently be purchased for approximately $1.72.

How much money does Biodesix make?

Biodesix (NASDAQ:BDSX) has a market capitalization of $134.11 million and generates $38.21 million in revenue each year. The company earns $-65,450,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis.

How many employees does Biodesix have?

The company employs 218 workers across the globe.

How can I contact Biodesix?

The official website for the company is www.biodesix.com. The company can be reached via phone at 303-417-0500 or via email at chris.brinzey@westwicke.com.

This page (NASDAQ:BDSX) was last updated on 3/28/2023 by MarketBeat.com Staff